{"id":391324,"date":"2015-09-21T00:00:00","date_gmt":"2015-09-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus1415-biopharma-ovarian-and-endometrial-cancers-managed-care-insights-physician-payer-forum-us-2015\/"},"modified":"2026-04-21T11:28:56","modified_gmt":"2026-04-21T11:28:56","slug":"pforus1415-biopharma-ovarian-and-endometrial-cancers-managed-care-insights-physician-payer-forum-us-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus1415-biopharma-ovarian-and-endometrial-cancers-managed-care-insights-physician-payer-forum-us-2015\/","title":{"rendered":"Ovarian and Endometrial Cancers (Managed Care Insights) | Physician &#038; Payer Forum | US | 2015"},"content":{"rendered":"<p><em>Impact of Specialty Pharmacy, Site of Care, and Practice Ownership on Physician Behavior <\/em><\/p>\n<p>Chemotherapy dominates treatment of both ovarian cancer and endometrial cancer, although Avastin, a targeted monoclonal antibody, and Lynparza, a new oral monotherapy, offer new hope for patients with more-advanced stages of ovarian cancer. As novel treatments emerge in the oncology space, the nation\u2019s healthcare payers are turning to management strategies to prioritize the most cost-effective therapies. Given the ever-increasing consolidation among oncology practices, hospital ownership is becoming a key factor in the delivery of cancer care. In this report, we examine the impact of several managed-care strategies on reimbursement and prescribing of ovarian and endometrial cancer drugs, including provider practice ownership models (e.g., physician-based versus hospital-based), utilization management strategies, site-of-care restrictions, narrow provider networks, and use of specialty pharmacies for oncology drug distribution.<\/p>\n","protected":false},"template":"","class_list":["post-391324","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-oncology","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391324\/revisions"}],"predecessor-version":[{"id":576938,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391324\/revisions\/576938"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}